Symposium 210

Crossing New Borders in IBD: Thoughts and Demands – From Mechanisms to Treatment

April 20–21, 2018
Estoril Centro de Congressos
Lisbon, Portugal

Program

Organized by:
FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany
Congress Department
Telephone: +49 (0) 761/15 14-0
Telefax: +49 (0) 761/15 14-359
E-Mail: symposia@falk-foundation-symposia.org
www.falk-foundation-symposia.org
11 credit hours (CME) have been awarded to the Symposium 210 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
Preface

The chronic inflammatory bowel diseases Crohn’s disease and ulcerative colitis have a major impact on patient’s health-related quality of life and the treatment-related costs place a significant burden on healthcare systems. In the last years, a better knowledge of the inflammatory pathways has promoted several alternative therapeutic options and new treatment goals, as well as new biomarkers and tools to predict and monitor the disease course. Biological therapies have provided important tools to treat IBD patients, as shown by anti-Tumor Necrosis Factor (TNF) agents, vedolizumab and ustekinumab. However, the wider spectrum of biologicals is sometimes also associated with an increased risk of infections and malignancies and the treating physician is encountered by many pharmacodynamic and pharmacokinetic questions with relevance for daily clinical practice. In parallel, treatment goals have shifted from symptomatic control towards more objective endpoints, namely mucosal healing, transmural healing (evaluated by cross sectional imaging), and histological remission. Historically, the medical management of IBD has been based on the use of several broadly acting anti-inflammatory drugs such as corticosteroids, thiopurines and mesalamine. New therapeutic options have been emerging and it becomes highly important to integrate all these concepts into algorithms easily perceived by physicians managing IBD patients.

The International Symposium 210 “Crossing New Borders in IBD: Thoughts and Demands – From Mechanisms to Treatment”, in Estoril/Lisbon from April 20-21, 2018 aims to critically discuss established and emerging new concepts in the diagnosis, treatment and monitoring of IBD. What we have: 1 - “omics” science in IBD with emphasis in Host-microbiom interaction; 2 - Revealing therapeutic targets for IBD treatment from cytokines, T-cells trafficking and fibrogenesis; 3 - Metrics in IBD, how to evaluate damage and severity; 4 - How to shape the old drugs; 5 - Integrating the old, the new and the future in algorithms. Special emphasis will be directed to the multidisciplinary management of complex IBD patients, namely intra-abdominal abscess, stenosis of small and large bowel in CD, anal disease, and treatment of extra intestinal manifestations. We also have a multidisciplinary session to address microscopic colitis as an inflammatory disease or only drugs induced disease entity? All speakers and moderators are internationally recognized IBD experts and build the basis for an up-to-date state-of-the-art symposium on IBD. The program was designed to provide opportunities for ample discussion and interaction with speakers, moderators and attendees.

We like to welcome you in Estoril/Lisbon. Lisbon is one of the oldest cities in the world, and the oldest in Western Europe, enjoys a Mediterranean climate and most of the Portuguese expeditions of the age of discovery left Lisbon during the 15-17th century. This period saw the rise of the exuberant Manueline style in architecture, which left its mark in many 16th century monuments. We hope that you will enjoy your stay!

The Chairmen of the Scientific Committee

Fernando Magro  
Axel Dignass
Crossing New Borders in IBD: Thoughts and Demands – From Mechanisms to Treatment

April 20–21, 2018
Estoril Centro de Congressos
Lisbon, Portugal

Start of Registration: Thursday, April 19, 2018 16.00 – 21.00 h at the congress office

Setting Up of Poster Session: Thursday, April 19, 2018 16.00 – 21.00 h

Congress Venue: Estoril Centro de Congressos Avenida Amaral 2765-192 Estoril Portugal

Scientific Organization: Prof. Dr. Fernando Magro Hospital de S. Joao Servico de Gastroenterologia Av. Prof. Hernani Monteiro 4200-319 Porto Portugal

Prof. Dr. Axel Dignass Medizinische Klinik I AGAPLESION Markus Krankenhaus Wilhelm-Epstein-Str. 4 60431 Frankfurt Germany

Symposium 210 is organized by Falk Foundation e.V.

Official Language: English
Friday, April 20, 2018

9.00 Welcome

Session I
“OMICS” science in IBD

Chair: L.A. Correia, Lisbon; G. Rogler, Zurich


9.30 Microbiota-derived metabolites – Homeostasis and bacterial activities P. Marteau, Paris

9.50 Tandem State-of-the-Art Lecture:
Translation of „omics“ science into clinical relevance for IBD C. Fiocchi, Cleveland

J. Menche, Vienna

10.30 Coffee break with poster session

Session II
Targeting inflammation

Chair: G.J. Mantzaris, Athens; A. Sturm, Berlin

11.00 T-cells and immunoregulatory cytokines in mediating chronic intestinal inflammation M.F. Neurath, Erlangen

11.20 T-cell trafficking in IBD: Mechanisms and therapeutic targets S. Schreiber, Kiel

11.40 Fibrogenesis in IBD – Mechanisms and targets F. Rieder, Cleveland

12.00 State-of-the-Art Lecture:
Translation of basic observations into clinical relevance in IBD S. Ghosh, Birmingham

12.30 Lunch break with poster session
Friday, April 20, 2018

Session III
Different sides of colitis

Chair: F. Carneiro, Porto; K. Geboes, Leuven

14.00 Microscopic colitis – Diagnosis and treatment
S. Miehlke, Hamburg

14.20 Microscopic colitis or only drugs?
D.S. Pardi, Rochester

14.40 Tandem Talk: Pathology perspective
Are all cases idiopathic?
P. Borralho, Lisbon

Drugs can not be ruled out
A. Ensari, Ankara

15.10 State-of-the-Art Lecture:
Is microscopic colitis an inflammatory bowel disease?
A. Münch, Linkoeping

15.40 Coffee break with poster session

Session IV
Evaluation of IBD

Chair: M. Barreiro de Acosta, Santiago de Compostela; F. Portela, Coimbra

16.10 Evaluating damage in Crohn’s disease
G. Fiorino, Milan

16.30 Assessing disease severity in Crohn’s disease
U. Kopylov, Ramat-Gan

16.50 Assessing disease severity in ulcerative colitis
J. Halvarson, Orebro

17.10 Defining end-points in clinical trials in IBD
S. Vermeire, Leuven

17.30 State-of-the-Art Lecture:
How can we transfer evidence from clinical trials to the management of individual IBD patients: Are we asking the right questions and studying the correct patients?
B.E. Sands, New York

18.00 Scientific discussion with snacks
Saturday, April 21, 2018

Session V
Shaping old drugs

Chair: J.P. Gisbert, Madrid; P. Lago, Porto

9.00 Why should we still use aminosalicylates for the treatment of IBD?  A. Dignass, Frankfurt
9.20 Do biosimilars provide the basis of a new paradigm in IBD management?  P. Michetti, Lausanne
9.40 Therapeutic drug monitoring: Is it essential or superfluous?  M. Löwenberg, Amsterdam

10.00 Coffee break with poster session

Session VI
Challenging problems in IBD management I

Chair: F. Gomollón, Zaragoza; P. Michetti, Lausanne

10.30 Intra-abdominal abscess - Medical treatment or surgery?
   Pro medical treatment  F. Carbonnel, Paris
   Pro surgery  P. Kienle, Mannheim

11.00 Stenosis of small and large bowel in CD - Medical treatment or surgery?
   Pro medical treatment  Y. Bouhnik, Paris
   Pro surgical treatment  A. Spinelli, Rozzano

11.30 Anal Disease - Medical treatment or surgery?
   Pro medical treatment  P. Gionchetti, Bologna
   Pro surgical treatment  A. D’Hoore, Leuven

12.00 Treatment of extraintestinal manifestations  S. Vavricka, Zurich
Saturday, April 21, 2018

12.20  Presentation of Poster Awards

12.30  Lunch break with poster session

Session VII
Challenging problems in IBD management II
Chair: A.R. Eliakim, Tel Hashomer; T. Kucharzik, Lüneburg

13.30  Treating patients with IBD and concomitant or previous cancer
L. Beaugerie, Paris

13.50  Exploring and treating CMV infection in IBD patients
B. Siegmund, Berlin

14.10  State-of-the-Art Lecture:
Balancing the risks and benefits of biologics
J.O. Lindsay, London

14.40  Coffee break with poster session

Session VIII
Guess the future
Chair: M. Allez, Paris; M.P. Ministro, Viseu

15.10  Integrating anti-integrins into the IBD treatment algorithm
G. van Assche, Leuven

15.30  Integrating anti-IL12 and anti-IL23 into the IBD algorithm
B.G. Feagan, London, CA

15.50  State-of-the-Art Lecture:
The future algorithms in IBD - Integrating everything?
W.J. Sandborn, La Jolla

16.20  Closing Remarks
F. Magro, Porto
A. Dignass, Frankfurt
**Poster Session**

Posters will be exhibited on April 20 and April 21, 2018. The authors will be in attendance during coffee and lunch breaks on both days. Set-up of poster session starts on April 19, 2018 at 16.00 h.

1.* Therapeutic drug monitoring of SB2: The accuracy of three different methods  
J. Afonso, F. Magro, C. Rocha, A.I. Vieira, H.T. Sousa, I. Rosa, S. Lopes,  
J. Carvalho, C.C. Dias; GEDII (Porto, Lisbon, Almada, Portimão, Gaia, PT)

2. Predictive factors of surgery in the course of Crohn's disease  
K. Agar, M. Medhioub, S. Jardak, L. Hamzaoui, A. Khsiba, M.M. Azouz  
(Nabeul, TN)

3. Value of neutrophil-to-lymphocyte ratio in predicting loss of response to  
anti- TNF treatment in Crohn’s disease patients: A single-center study  
K. Agar, M. Medhioub, S. Jardak, L. Hamzaoui, A. Khsiba, M.M. Azouz  
(Nabeul, TN)

4. Predictive factors of postoperative septic complications in Crohn’s disease:  
A single-center study  
K. Agar, M. Medhioub, S. Jardak, L. Hamzaoui, A. Khsiba, M.M. Azouz  
(Nabeul, TN)

5. Predictive factors of penetrating complications in Crohn’s disease: A single- 
center study  
K. Agar, M. Medhioub, S. Jardak, L. Hamzaoui, A. Khsiba, M.M. Azouz  
(Nabeul, TN)

6. Can the first presentation of ulcerative colitis predict the course?  
Z. Akpinar, E. Saritas Yuksel, B. Unsal, C. Cekic, B. Ogut Aydin, F. Topal,  
H. Camyar (Izmir, TR)

7. Inflammatory bowel disease in the UK: Is care improving?  
L. Alrubaiy, I. Arnott, A. Protheroe, M. Roughton, J.G. Williams (Swansea,  
Edinburgh, London, GB)

8. Clinicians’ knowledge about the ionizing radiation of the common investigations used in inflammatory bowel disease  
L. Alrubaiy, S. Al-Rubaye, I. Rikaby, C. Lye Ch'ng (Swansea, London, GB)

9.* Crohn’s and ulcerative colitis questionnaire-8 (CUCQ-8), a valid and quick quality of life measure in IBD  
L. Alrubaiy, P. Dodds, H.A. Hutchings, J.G. Williams (Swansea, GB)

10.* Infliximab or ciclosporin for steroid-resistant acute severe ulcerative colitis? Results of a pragmatic randomised trial and economic evaluation (CONSTRUCT)  
11. Significance of IL-17/IL-23 axis and TGF-β1 expression in pathogenesis of ulcerative colitis
   Y. Ananiev, K. Ivanova, V. Velev, M. Penkova, R. Tenev, M.V. Gulubova
   (Stara Zagora, BG)

12. The peculiarities of intestinal microflora in patients with prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs)
   A. Antonenko, T.V. Beregova, L. Ostapchenko (Kiev, UA)

13. Evaluation and comparison of serology of viral infection and tuberculosis screening in Central versus Southern Italy: A difference for infectious risk and consequent treatment decisions
   M. Ardesia, G. Costantino, F. Ridolfi, C. Todeschini, A.L. Iasci, S. Bologna,
   W. Fries, E. Brunelli (Senigallia, Messina, IT)

14. Correlation between inflammatory biomarkers and endoscopic scores in ulcerative colitis: Thus extension makes the difference?
   C. Arieira, F. Dias de Castro, M.J. Moreira, J. Cotter (Guimaraes, PT)

15. IBD – Is it a risk factor for the diagnosis of hepatic steatosis?
   C. Arieira, S. Monteiro, S. Xavier, F. Dias de Castro, J. Magalhães, M.J. Moreira,
   C. Marinho, J. Cotter (Guimaraes, PT)

16. Crohn's disease: What can we expect from the course of the disease?
   C. Arieira, T. Cúrdia Gonçalves, F. Dias de Castro, M.J. Moreira, J. Cotter
   (Guimaraes, PT)

17. Incidence of preventable diseases in IBD patients candidates for biological treatment
   A. Atanassova, A. Georgieva (Varna, BG)

18. Why should we monitor glomerular filtration rate in children with ulcerative colitis?
   K. Bak-Drabik, A. Chobot, J. Porebska, A. Zabka (Zabrze, PL)

19. Diagnostic yield of colonoscopic images and biopsy results by tuberculosis culture in patients with distal part of terminal ileum ulcerations
   M. Basaranoglu (Istanbul, TR)

20. Prevalence of ulcerative colitis and Crohn ileocolitis in patients with celiac disease
   M. Basaranoglu (Istanbul, TR)

21. Idiopathic or drug-induced acute pancreatitis in patient with Crohn's disease
   D. Bekic, Z. Belosic Halle, V. Bakula, K. Luetic (Zagreb, HR)

22. Crohn's disease – An unusual first presentation
   Z. Belosic Halle, D. Bekic, V. Bakula, K. Luetic (Zagreb, HR)

23. Early diagnosis in inflammatory bowel disease (IBD) – A pilot study
   A. Belvedere, R. Scoglio, M.L. Bruno, U. Alecci, A. Crescenti, S. Inferrera,
   L. Di Geronimo, S. Marino, A. Alibrandi, W. Fries (Messina, IT)
24. Association between ulcerative colitis and polymyositis: An extraintestinal manifestation of ulcerative colitis or an intestinal sign of the polymyositis: A case report
   E. Ben Jazia, I. Jemni, I. Akkari, S. Mrabet (Sousse, TN)
25. Safety and effectiveness of long-term azathioprine maintenance treatment in inflammatory bowel disease
   E. Ben Jazia, I. Akkari, S. Mrabet (Sousse, TN)
26. Prevalence and clinical significance of hypergammaglobulinemia in inflammatory bowel disease patients
   E. Ben Jazia, I. Akkari, S. Mrabet, I. Jemni (Sousse, TN)
27. Factors associated with non-delayed surgery for intra-abdominal abscesses complicating Crohn’s disease
28. Risk factors associated with high levels of fatigue in patients with inflammatory bowel disease in remission
29. Efficacy of intravenous steroids in moderate colitis refractory to oral steroids
30. A change in ΔMCV predicts mucosal healing in patients with Crohn’s disease under combination therapy
31. Ultrasonography and perianal involvement in inflammatory bowel disease
   S. Bernardo, P. Lago, T. Moreira, D. Ferreira, I. Pedroto, F. Castro-Pocas (Lisbon, Porto, PT)
32.* Predicting outcome in acute severe ulcerative colitis: Comparison of the Oxford, Edinburgh, Lindgren and endoscopic Mayo scores
33. Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with inflammatory bowel disease
34. A case report: Anti-VEGF agent bevacizumab in a patient with Crohn’s disease
35. Is azathioprine effective in the treatment of Crohn’s disease?
   A. Brahem, A. Hammami, S. Hachicha, H. Jaziri, N. Elleuch, A. Ben Slama, M. Ksiaa, S. Ajmi, A. Jmaa (Sousse, TN)
36.* Six-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
C. Cassieri, R. Pica, E.V. Avallone, G. Brandimarte, M. Zippi, P. Crispino, D. De Nitto, P.G. Lecca, P. Vernia, P. Paoluzi, E.S. Corazziari (Rome, IT)

37. Mesalazine monotherapy for maintenance of remission in ulcerative colitis patients in Turkish population

38. Prevalence of effective vaccination for hepatitis B in patients with inflammatory bowel disease
A.M. Chiosa, I. Popa, R.C. Popa, A.-G. Dorobat, A. Savin, M. Dranga, C. Cijevschi Prelipcean (Iasi, RO)

39. Prevalence of hepatitis B virus infection markers in patients with inflammatory bowel disease in a hepatitis B endemic region
A.M. Chiosa, I. Popa, R.C. Popa, A. Savin, A.-G. Dorobat, C. Mihai (Iasi, RO)

40. The effect of 1-year therapy with anti-TNF-α monoclonal antibodies on the lipid profile in patients with inflammatory bowel disease
C. Cijevschi Prelipcean, R.C. Popa, A. Savin, O. Gavrilescu, I. Popa, A.-G. Dorobat, A.M. Chiosa, M. Dranga, C. Mihai (Iasi, RO)

41. Transfer of responsibility for self-care from the pediatric to the adult patient with Crohn’s disease: Case report
A. Clim, R. Maxim, A. Plesa (Iasi, RO)

42. Outcomes following anti-TNF discontinuation and the risk of relapse in inflammatory bowel disease: A single-centre experience
L. Coffey, A. Mullen, J. Leyden, P. MacMathuna (Dublin, IE)

43. Can we avoid surgery in Crohn’s disease with spontaneous abdominal abscesses?
J.M. Costa, D. Soares, R. Goncalves, J.B. Soares (Braga, PT)

44. Changing natural history in IBD – Steroid-free remission and surgery in two cohorts (≤ 2009 and > 2009): An interplay between disease pattern, biologics and adherence
G. Costantino, M. Naim, M. Scolaro, A. Viola, T. Pinto-Vraca, V. Pisana, A. Alibrandi, W. Fries (Messina, IT)

45. MaRIA score in the assessment of disease activity in patients with ileocolonic Crohn’s disease: The correlation between radiological, clinical and endoscopic scores
M. Crncevic Urek, J. Curic, L. Prka, D. Kardum, M. Banic (Zagreb, HR)

46.* Experimental model of fistulizing Crohn’s disease: Beneficial effect of topical application of adipose tissue-derived mesenchymal stromal cells
H.S. de Souza, V. Alvarenga Jr., H. Nanini, B. Pego, N. Bonfa, M. Castelo-Branco, W. Baetas, A. Schanaider (Rio de Janeiro, BR)
47. Anxiety and depression in inflammatory bowel disease
C.I. Deliu, O.M. Diaconu, D. Neagoe, A.-V. Genunche-Dumitrescu, N. Deliu
(Bals, Craiova, RO)

48. Treatment and quality of life in inflammatory bowel disease
C.I. Deliu, O.M. Diaconu, A.-V. Genunche-Dumitrescu, D. Neagoe, N. Deliu
(Bals, Craiova, RO)

49. Cerebral venous thrombosis is a rare complication of ulcerative colitis
– Case report
R. Despot, V. Zitko, E. Marusic, M. Simunovic, M. Lahman Doric (Split, HR)

50. Status of vitamin D in patients with inflammatory bowel disease: A study in a
tertiary care center from Northeastern Romania
A.-G. Dorobat, C. Cijevschi Prelipcean, O. Gavrilescu, M. Dranga, I. Popa,
O.I. Gavril, R.C. Popa, A. Savin, A.M. Chiosa, C. Mihai (Iasi, RO)

51. Particularities of treatment in elderly people with inflammatory bowel
disease: A study in a tertiary care center from Northeastern Romania
A.-G. Dorobat, C. Mihai, R.C. Popa, A. Savin, A.M. Chiosa, O.I. Gavril,
O. Gavrilescu, M. Dranga, I. Popa, C. Cijevschi Prelipcean (Iasi, RO)

52. Prevalence of anemia in patients with inflammatory bowel diseases (IBD) in
a tertiary center in Romania
M. Dranga, O. Gavrilescu, I. Popa, R.C. Popa, C. Cijevschi Prelipcean,
C. Mihai (Iasi, RO)

53. Metastatic vulvar Crohn's disease: A rare entity
N. Elleuch, W. Dahmani, A. Ben Slama, H. Jaziri, A. Hammami, B. Hasnaoui,
A. Brahem, M. Ksiaa, A. Jmaa (Sousse, TN)

54. Prevalence of chronic hepatitis B in Tunisians patients with inflammatory
bowel disease
N. Elleuch, W. Dahmani, A. Ben Slama, A. Hammami, B. Hasnaoui, H. Jaziri,
A. Brahem, M. Ksiaa, A. Jmaa (Sousse, TN)

55. Screening and management of latent tuberculosis in inflammatory bowel
disease patients candidates for anti-TNF therapy
N. Elleuch, W. Dahmani, A. Ben Slama, A. Hammami, B. Hasnaoui, H. Jaziri,
A. Brahem, M. Ksiaa, A. Jmaa (Sousse, TN)

56. Can we predict the efficacy of anti-TNF agents?
N. Elleuch, W. Dahmani, A. Ben Slama, A. Hammami, H. Jaziri, A. Brahem,
M. Ksiaa, A. Jmaa (Sousse, TN)

57. Impact of endoscopic remission on the ulcerative colitis evolution
M. Fekih, M. Serghini, M. Ben Abbes, N. Ben Mustapha, A. Labidi, J.
Boubaker (Tunis, TN)

58. Long-term outcome of patients with Crohn's disease treated with corticosteroids:
A retrospective comparative study
M. Fekih, M. Hafi, M. Serghini, N. Ben Mustapha, A. Labidi, J. Boubaker
(Tunis, TN)
59. Sicily (Italy) confirms a high prevalence of inflammatory bowel disease (IBD) – A population-based study in the Province of Messina

60. Short-term efficacy of the biosimilar CT-P13 in Greek patients with ulcerative colitis: A retrospective single-center study
   M. Galanopoulos, A. Christidou, I. Tziortziotis, F. Gkeros, M. Vrika, C. Pontas, E. Archavlis, N. Viazis, G.J. Mantzaris (Athens, GR)

61. BAFF, its homologue APRIL and BAFF-R and infliximab therapy in patients with inflammatory bowel disease
   M. Gazouli, G. Karamanolis, L.A. Sechi (Athens, Sassari, GR)

62. Extraintestinal manifestation in inflammatory bowel disease and the relationship between bone mineral density, disease activity and remission maintenance therapy
   A.-V. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, D. Neagoe, O.M. Diaconu, C.I. Deliu, A. Badea (Craiova, RO)

63. Combined therapy versus monotherapy in the treatment of severe steroid-refractory Crohn's disease
   A.-V. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, C.I. Deliu, O.M. Diaconu, A. Badea (Craiova, RO)

64. Clinical course of Crohn’s disease followed-up in a period of six years in one reference center
   A. Georgieva, A. Atanassova, I.A. Kotzev (Varna, BG)

65.* The transcription factor NFATc3 promotes intestinal inflammation by suppression of regulatory T cells
   K. Gerlach, V. Popp, M.F. Neurath, B. Weigmann (Erlangen, DE)

66. Hepatic manifestations associated to inflammatory bowel diseases
   A. Hammami, N. Elleuch, W. Dahmani, B. Hasnaoui, M. Ksiaa, H. Jaziri, A. Brahem, S. Ajmi, A. Ben Slama, A. Jmaa (Sousse, TN)

67. Colectomy rate in acute severe colitis responding to rescue medical therapy
   A. Hammami, B. Hasnaoui, N. Elleuch, W. Dahmani, M. Ksiaa, H. Jaziri, A. Brahem, S. Ajmi, A. Ben Slama, A. Jmaa (Sousse, TN)

68. Is it possible to prevent clinical recurrence of Crohn’s disease after surgical resection?
   A. Hammami, S. Hachicha, B. Hasnaoui, M. Ksiaa, H. Jaziri, N. Elleuch, A. Brahem, S. Ajmi, A. Ben Slama, A. Jmaa (Sousse, TN)

69. Terminal ileitis is not always Crohn's disease: Correlation between endoscopic and histological findings
   A. Hammami, B. Hasnaoui, N. Elleuch, W. Dahmani, M. Ksiaa, H. Jaziri, A. Brahem, S. Ajmi, A. Ben Slama, A. Jmaa (Sousse, TN)
70. Adherence to medical treatment in patients with inflammatory bowel disease
L. Hamzaoui, S. Jardak, M. Medhioub, M. Bouassida, M. Mahmoudi, A. Khsiba, M.M. Azouz (Nabeul, TN)

71. Predictive factors of a clinical severe course of Crohn's disease: A monocentric study
L. Hamzaoui, K. Agar, M. Medhioub, M. Bouassida, M. Mahmoudi, A. Khsiba, M.M. Azouz, E. Chelbi (Nabeul, TN)

72. Prevalence and risk factors for non-alcoholic fatty liver disease in Crohn's disease
L. Hamzaoui, A. Ben Mohamed, A. Khsiba, M. Medhioub, M. Mahmoudi, M.M. Azouz (Nabeul, TN)

73. Predictors of negative C-reactive protein in active Crohn's disease
L. Hamzaoui, A. Ben Mohamed, M. Mahmoudi, A. Khsiba, M. Medhioub, M.M. Azouz (Nabeul, TN)

74. Extraintestinal manifestations of inflammatory bowel disease: Prevalence and risk factors
L. Hamzaoui, S. Jardak, A. Khsiba, M. Mahmoudi, M. Medhioub, M.M. Azouz (Nabeul, TN)

75. Results from a retrospective analysis of colonoscopies for inflammatory bowel disease and colorectal polyposis in a Tunisian center care
L. Hamzaoui, B. Bouchabou, M. Mahmoudi, M. Medhioub, A. Khsiba, M.M. Azouz (Nabeul, TN)

76. Prevalence of axial spondyloarthritis associated with inflammatory bowel diseases in a Tunisian cohort

77. Anemia in inflammatory bowel disease
L. Hamzaoui, K. Agar, M. Medhioub, A. Khsiba, M. Mahmoudi, M.M. Azouz (Nabeul, TN)

78. Short-term and long-term outcomes of endoscopic dilatation for Crohn's disease strictures
L. Hartmann, M. Treiber, R.M. Schmid, W. Schepp, F. Gundling (Munich, DE)

79. Correlation between endoscopic lesions and cyclosporine response in steroid-refractory ulcerative colitis
B. Hasnaoui, H. Jaziri, A. Hammami, M. Ksiaa, N. Elleuch, A. Brahem, S. Ajmi, A. Ben Slama, A. Jmaa (Sousse, TN)

80. Predictive factors of colectomy in patients with steroid-refractory acute severe ulcerative colitis
B. Hasnaoui, A. Hammami, W. Dahmani, M. Ksiaa, N. Elleuch, H. Jaziri, A. Brahem, S. Ajmi, A. Ben Slama, A. Jmaa (Sousse, TN)
81. Cyclosporine in acute severe steroid-refractory ulcerative colitis: Short- and long-term outcomes
B. Hasnaoui, A. Hammami, S. Hachicha, M. Ksiaa, N. Elleuch, H. Jaziri, A. Brahem, S. Ajmi, A. Ben Slama, A. Jmaa (Sousse, TN)

82. Mitochondrial DNA is a pro-inflammatory damage-associated molecular pattern (DAMP) released during active IBD

83.* Validation of the CUCQ questionnaire with stoma extension in patients with acute ulcerative colitis in the CONSTRUCT trial
H.A. Hutchings, L. Alrubaiy, A. Watkins, W.-Y. Cheung, A.C. Seagrove, I.T. Russel, J.G. Williams (Swansea, GB)

84. CRP/albumin ratio: Predictive factor of the response to corticosteroids in acute severe colitis
S. Jardak, M. Medhioub, K. Agar, L. Hamzaoui, A. Khsiba, M.M. Azouz (Nabeul, TN)

85. Co-existence of liver steatosis and inflammatory bowel disease: A retrospective study
S. Jardak, M. Medhioub, K. Agar, L. Hamzaoui, A. Khsiba, M.M. Azouz (Nabeul, TN)

86. Ulcerative colitis: Role of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in predicting disease severity
S. Jardak, M. Medhioub, K. Agar, L. Hamzaoui, A. Khsiba, M.M. Azouz (Nabeul, TN)

87.* Ikaros family transcription factors associate with inflammatory switched-Tregs that are elevated in the bowels of IBD patients
L.E. Jeffery, T.-A. Verrill, A. Ueno, J. Li, S. Ghosh (Birmingham, GB; Calgary, CA; Tokyo, JPN; Beijing, CHN)

88. The vitamin D status and level of fecal calprotectin in inflammatory bowel disease in children
A. Jelicic Kadic, E. Runjic, V. Zitko, R. Despot (Split, HR)

89. An association study of long non-coding RNAs in the pathogenesis of inflammatory bowel diseases

90. Crohn’s disease clinical phenotypes have distinct gut microbial signatures: An in silico approach
G. Kolios, N. Dovrolis, I. Drygiannakis, E. Filidou, L. Kandilogiannakis, K. Arvanitidis, I. Tentes, V. Valatas (Alexandroupolis, Heraklion, GR)
91.* Cytokine receptor profiling in human colonic subepithelial myofibroblasts: A differential effect of Th polarization associated cytokines in intestinal fibrosis
G. Kolios, E. Filidou, I. Drygiannakis, K. Arvanitidis, S. Vradelis, G. Kouklakis, V. Valatas (Alexandroupolis, Heraklion, GR)

92. Risk factors for poor postoperative outcome in patients with Crohn’s disease undergoing ileocecal resection

93. Long-term outcome of Crohn’s disease patients treated with methotrexate: A retrospective monocenter study

94.* The role of the Tec kinase ITK and the transcription factor NFATc1 in disease pathogenesis of inflammatory bowel disease
K. Lechner, S. Mott, M.F. Neurath, B. Weigmann (Erlangen, DE)

95. Vedolizumab levels and endoscopic and clinical remission in patients with Crohn’s disease and ulcerative colitis on vedolizumab therapy
E. Legaki, G. Michalopoulos, K. Makris, M. Gazouli (Athens, Piraeus, GR)

96. What is hidden beneath chronic bloody diarrhea in two-year-old girl?
T. Lesar, A. Jaklin-Kekez (Zagreb, HR)

97.* Cell death independent physiological cell shedding in the absence of GGTase- mediated prenylation in intestinal epithelium
R. Lopez-Posadas, L.C. Martinez-Sanchez, T. Kisseleva, V. Thonn, M.O. Bergö, A.F. Watson, M.F. Neurath, R. Atreya (Erlangen, DE; Gothenburg, SE; Norwich, GB)

98. The clinical course of Hermanski-Pudlak syndrome associated with granulomatous colitis: Relations with genotype in patients from western Ukraine
M. Lozynska, L. Lozynska, A. Plawski, R. Lozynskyy, I. Vtyvytskyy, B. Tretiak (Lviv, UA; Poznan, PL)

99. Clinical characteristics and L1007fs mutation of NOD2 gene in patients with Crohn’s disease from Western Ukraine, associated with colorectal cancer and without cancer
L. Lozynska, M. Lozynska, A. Plawski, O. Lukavetsky (Lviv, UA; Poznan, PL)

100. Evaluation of CD40 and CD80 receptors in the colonic mucous membrane of children with Crohn’s disease
M. Maciorkowska, M. Zakrzewski, W. Ustymowicz, I. Roszko-Kirpsza, B. Kaminska, A. Szlagatys-Sidorkiewicz, K. Guzinska-Ustymowicz, E. Maciorkowska (Bialystok, Gdansk, PL)

101. Whipple’s disease – Clinical case
M. Maciorkowska, M. Zakrzewski, W. Ustymowicz, K. Guzinska (Bialystok, PL)
Different histological indexes for the assessment of ulcerative colitis activity
F. Magro, J. Lopes, P. Borralho, S. Lopes, R. Coelho, J. Cotter, F. Dias de Castro,
H. Tavares de Sousa, M. Salgado, P. Andrade, A.I. Vieira, P. Figueiredo,
P. Caldeira, A. Sousa, M.A Duarte, F. Ávila, J. Silva, J. Moleiro, S. Mendes,
S. Giestas, P. Ministro, P. Sousa, R. Gonçalves, B. Gonçalves, A. Oliveira,
I. Rosa, M. Rodrigues, C. Chagas, C.C. Dias, J. Afonso, K.I. Geboes, F. Carneiro;
Portuguese IBD Study Group (GEDII) (Porto, Lisbon, Guimaraes, Portimao,
Faro, Almada, Ponta Delgada, Coimbra, Viseu, Braga, Amadora, PT;
Leuven, BE)

The role of gamma-secretase subunit PSEN1 in intestinal inflammation
M. Mahapatro, J. Shen, M.F. Neurath, S. Wirtz, C. Becker (Erlangen, DE;
Boston, US)

The serotonin role in the intestine motor function violation in patients with
ulcerative colitis
G.S. Maslova, I.M. Skrypnyk, R.I. Skrypnyk (Poltava, UA)

Diagnostic accuracy of tissue transglutaminase antibodies for detecting
persistent villous atrophy among adult patients on a gluten-free diet
R. Maxim, A. Plesa, O.C. Stoica, C. Stanciu, T. Anca (Iasi, RO)

Named patient supply programs allow earlier access to treatments for
complex patients: UK multicentre ustekinumab experience
M.J. McDonnell, M. Samaan, S. Subramanian, M. Bettey, F. Cummings
(Southampton, London, Liverpool, GB)

Association between inflammatory bowel disease and celiac disease:
About 4 cases
M. Medhioub, L. Hamzaoui, A. Ben Mohamed, A. Khsiba, M.M. Azouz
(Nabeul, TN)

Active disease prevention in inflammatory bowel disease through exercise
C. Mihai, I.V. Popa, O. Gavrilescu, M. Dranga, R.C. Popa, A.M. Chiosa,
A. Savin, A.-G. Dorobat, C. Cijevschi Prelipcean (Iasi, RO)

Acne vulgaris related to ulcerative colitis treated with infliximab standard
therapy
V. Mokricka, P. Zalizko, J. Pokrotnieks, A. Pukitis (Riga, LV)

Are lower levels of fecal calprotectin reassuring in Crohn’s disease patients?
S. Monteiro, F. Dias de Castro, S. Leite, M.J. Moreira, J. Cotter (Guimaraes,
Braga, PT)

C-reactive protein/albumin ratio is a good predictor of response to intrave-
nous corticosteroids in acute severe ulcerative colitis
S. Monteiro, T. Curdia Goncalves, F. Dias de Castro, S. Leite, M.J. Moreira,
J. Cotter (Guimaraes, Braga, PT)

Surgical aspects of Crohn’s disease
S. Mrabet, I. Akkari, I. Massoudi, R. Letaief, I. Jemni, F. Hemila, E. Ben
Jazia (Sousse, TN)
113. Appendiceal Crohn’s disease presenting as acute appendicitis
   S. Mrabet, I. Akkari, R. Letaief, F. Hemila, E. Ben Jazia (Sousse, TN)

114. Surgical treatment in Crohn’s disease
   S. Mrabet, I. Akkari, I. Jemni, E. Ben Jazia (Sousse, TN)

115. Appendectomy in Crohn’s disease: Is it a risk factor or a mis-diagnosis?
   S. Mrabet, I. Jemni, I. Akkari, R. Letaief, F. Hemila, E. Ben Jazia (Sousse, TN)

116. Is transabdominal ultrasonography as effective as CDAI and MR enterography
   in Crohn’s disease?
   B. Ogut Aydin, F. Topal, E. Saritas Yuksel, Z. Akpinar, B. Unsal (Izmir, TR)

117. First experiences with vedolizumab therapy in a Croatian tertiary center
   V. Orsic Fric, V. Borzan, B. Borzan (Osijek, HR)

118. Can we predict the adverse reactions in patients with inflammatory bowel
disease treated with azathioprine?
   K. Pavlovska, M. Slaninka Miceska, M. Petrushevskva, L. Efremovska,
   M. Miceska, V. Andreevski (Skopje, MK)

119. Clinical aspects of microscopic colitis
   O. Petracsu, A. Solomon (Sibiu, RO)

120. Challenges in patients with ulcerative colitis and primary sclerosing cholangitis
   O. Petracsu, A. Boicean (Sibiu, RO)

121. What factors affect the processes of fibrosis in pediatric inflammatory bowel
diseases?
   S. Pieczarkowski, P. Tomasik, P. Kwinta, A. Wedrychowicz, K. Kowalska-Duplaga,
   Z. Grzenda, M. Sladek, K. Fyderek (Cracow, PL)

122. Sleep impairment and inflammatory bowel disease activity
   I.V. Popa, O. Gavrilescu, M. Dranga, R.C. Popa, A.M. Chiosa, A. Savin,
   A.-G. Dorobat, C. Mihai, C. Cijevschi Prelipcean (Iasi, RO)

123. The role of Helicobacter pylori eradication on disease activity measures in
   patients with Crohn’s disease
   R.C. Popa, A. Savin, O. Gavrilescu, I. Popa, A.-G. Dorobat, A.M. Chiosa,
   M. Dranga, C. Mihai, C. Cijevschi Prelipcean (Iasi, RO)

124.* TH1 transcription factor T-bet as a new target for Crohn’s disease therapy
   V. Popp, K. Gerlach, J. Kuhlmann, B. Weigmann (Erlangen, Marburg, DE)

125. Simultaneous presentation of Crohn’s disease in siblings: Genes or environment?
   J. Porebska, A. Chrobot, A. Krzywicka, K. Bak-Drabik, A. Zabka, J. Kwiecien
   (Zabrze, PL)

126. The results of the newfound Department of Gastroenterology with Endoscopy
   Unit of Prijedor Hospital
   G. Predojevic, E. Iglic (Prijedor, BA)

127. Correlation of fecal calprotectin with endoscopically defined activity index
    and localization in IBD patients
   D. Prohic, A. Selimovic, A. Puhalovic, K. Nahadovic (Sarajevo, BA)
128. The selectivity of the neutrophils infiltration in ulcerative colitis may be dependent on the claudin-4 expression
A. Pryczynicz, K. Guzinska-Ustymowicz, M. Niziol, J. Zinczuk, K. Zareba, M. Maciorkowska (Bialystok, PL)

129. Irritable bowel syndrome may be associated with elevated hepatic enzyme and metabolic syndrome
Y.M.K. Rashid, N.A. Zaki (Sohag, EG)

130. Can the inflammatory bowel disease biologics registry lead to improved quality of care?
I. Rikaby, L. Alrubaiy, H.A. Hutchings, J.G. Williams (Cardiff, Swansea, GB)

131. Systematic review of the clinical disease severity indices for inflammatory bowel disease
I. Rikaby, L. Alrubaiy, M. Sageer, H.A. Hutchings, J.G. Williams (Swansea, Cardiff, GB; Massachusetts, USA)

132. Paradoxical reaction to anti-tuberculosis therapy in a patient with disseminated tuberculosis under infliximab
M. Rocha, M. Salgado, B. Ferreira, I. Pedroto (Porto, PT)

133. A non-treated Crohn's disease flare during pregnancy: The impact of perianal disease

134. Sustained deep remission with intermittent low-dose rifaximin schema for antibiotic-dependent pouchitis – A 2-year open-label study data
J. Roseira, H.T. Sousa, P. Quérois, A.M. Vaz, A.C. Cunha, L. Contente, H. Guerreiro (Faro, PT)

135. Extraintestinal manifestations of Crohn’s disease and its clinical features among patients in Split-Dalmatia County, Croatia
B. Rosic Despalatovic, A. Bratanic, B. Pavic, A. Tonkic (Split, HR)

136. The severity of endoscopic lesions in ulcerative colitis: Between the assessment of endoscopist and the Ulcerative Colitis Endoscopic Index of Severity score
A. Sabbek, N. Elleuch, W. Dahmani, A. Ben Slama, H. Jaziri, A. Hammami, M. Ksiaa, A. Jmaa (Sousse, TN)

137. Correlation between Crohn's Disease Activity Index and the severity of disease flare-up
L. Safer, A. Guediche, R. Baklouti, A. Sabbek, M. Zakhama, W. Bouhlel, W. Ben Mansour, M.H. Loghmari (Monastir, TN)

138. Azathioprine and Crohn’s disease: Efficacy and tolerance
L. Safer, A. Guediche, A. Sabbek, F. Aissaoui, M.H. Loghmari, W. Ben Mansour, W. Bouhlel (Monastir, TN)

139. Predictive factors for a severe clinical course in ulcerative colitis
L. Safer, M. Zakhama, W. Ben Mansour, W. Bouhlel, A. Guediche, M.H. Loghmari (Monastir, TN)
140. Predictive factors of recurrence of Crohn’s disease after ileocecal resection
L. Safer, A. Guediche, R. Baklouti, F. Aissaoui, M. Zakhama, W. Ben Mansour,
W. Bouhlel, M.H. Loghmari (Monastir, TN)

141. Which ulcerative colitis patients are at risk of having proximally extending
disease?
E. Saritas Yuksel, B. Unsal, Z. Akpinar, C. Cekic, F. Topal, B. Ogut Aydin,
H. Camyar (Izmir, TR)

142. The prevalence of Clostridium difficile infection in patients with inflammatory
bowl disease – A study in a tertiary care center in Romania
A. Savin, R.C. Popa, A.-G. Dorobat, A.M. Chiosa, O. Gavrilesco,
C. Cijevschi Prelipcean, C. Mihai (Iasi, RO)

143. The correlation between fecal calprotectin and disease location in patients
with Crohn’s disease
A. Savin, R.C. Popa, A.-G. Dorobat, I.V. Popa, O. Gavrilescu, C. Cijevschi
Prelipcean, C. Mihai (Iasi, RO)

144. Patient perception and approval of fecal microbiota transplantation (FMT) as
an alternative treatment option for ulcerative colitis
S. Schuler-Roggenbrodt, L. Hartmann, C. Schuler, B. Haller, W. Schepp,
F. Gundling (Munich, DE)

145. The efficacy of 5-ASA and infliximab therapy in patients with Crohn’s
disease

146. Role of laboratory markers in pediatric inflammatory bowel disease
R. Shentova, P. Yaneva, M. Baycheva, P. Hadjiiski, D. Kofinova, C. Zhelev
(Sofia, BG)

147. A rare cause of retroperitoneal fibrosis
S. Shwana, A. Ur Rahman, E. Slowinska (Merthyr Tydfil, GB)

148. Violations of the intestinal microbiocenosis on the background of non-specific
ulcerative colitis exacerbation
I.M. Skrypnyk, G.S. Maslova, R.I. Skrypnyk (Poltava, UA)

149. Clinical and psychological features of patients with different variants of
non-specific ulcerative colitis
I.M. Skrypnyk, G.S. Maslova, R.I. Skrypnyk (Poltava, UA)

150. Correlation between endoscopic and histological activity in IBD with level of
the FCP
J. Sladoje, G. Pusicic, G. Lucic, D. Savic (Uzice, RS)

151. Treatment of patients with ulcerative colitis and arthritis
V. Sulyma (Dnipropetrovsk, UA)

152. Ulcerative colitis and adenocarcinoma – Case report at 24-year-old
pregnant with long-lasting IBD
R. Tamburic, J. Petkovic-Dabic, M. Kostic, L. Jovandic, S. Dabic (Banja
Luka, BA)
153. Eosinophilic esophagitis, clinical practice: Case report and literature review
R. Tamburic, J. Petkovic-Dabic, M. Kostic, S. Trbojevic (Banja Luka, BA)

154. Gene expression profile of endoscopically active and inactive ulcerative colitis: Preliminary data
C. Tieranu, T. Manuc, M. Dobre, E. Milanesi, I.E. Plesea, M. Manuc, I. Tieranu, C.M. Preda, M.M. Diculescu, D. Ion, M.E. Ionescu, G. Becheanu (Bucharest, RO)

155. The importance of an early proactive anti-TNF therapy monitoring in patients with ulcerative colitis
A. Tudora (Timisoara, RO)

156. Elements influencing health-related quality of life in patients with collagenous colitis
A. Tudora (Timisoara, RO)

157. Is postoperative course of rescue colectomy in severe acute ulcerative colitis affected by preoperative biologic treatment?
B. Unsal, Z. Akpinar, E. Saritas Yuksel, F. Topal, B. Ogut Aydin, C. Cekic (Izmir, TR)

158. The expression of MMP-7 dependent of CD45-positive cells in lamina propria of inflammatory bowel disease
W. Ustymowicz, A. Pryczynicz, M. Maciorkowska, L. Zakrzewski, J. Zinczuk, K. Zareba, E. Maciorkowska (Bialystok, PL)

159. Epidemiology, complication, extraintestinal manifestation and treatment of inflammatory bowel disease in Sanliurfa region of Turkey
A. Uyanikoglu, A. Ciftci (Sanliurfa, TR)

160. Hyperbaric oxygen therapy in the treatment of ulcerative colitis
A. Uzunova, Z. Kirvikov (Sofia, BG)

161. Efficacy of vedolizumab in inflammatory bowel disease refractory to anti-TNF-α

162. The diagnostic yield of small bowel capsule endoscopy in postsurgical Crohn’s disease

163. Switching from subcutaneous anti-TNF to intravenous anti-TNF in ulcerative colitis: A multicenter study
164. TrueColours Ulcerative Colitis (TCUC): Will patients with UC complete digital questionnaires in real-time?

165.* Transcription factor GATA-3 in ulcerative colitis: Use of specific DNAzymes to inhibit experimental colitis
B. Weigmann, V. Popp, K. Gerlach, A. Turowska, H. Garn, R. Atreya, I.-C. Ho, H. Renz, M.F. Neurath (Erlangen, Marburg, DE; Boston, US)

166. Clinical and translational outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease receiving vedolizumab

167.* Perianal Crohn’s disease – Association with significant inflammatory activity in proximal small bowel segments
S. Xavier, T. Curdia Goncalves, F. Dias de Castro, J. Magalhaes, B. Rosa, M.J. Moreira, J. Cotter (Guimaraes, Braga, PT)

168. Strictureing Crohn’s disease – Can we predict need for surgery at first hospitalization?
S. Xavier, T. Curdia Goncalves, F. Dias de Castro, J. Magalhaes, M.J. Moreira, J. Cotter (Guimaraes, Braga, PT)

169. A case of pyoderma gangraenous associated with ulcerative colitis
P. Yaneva, R. Shentova, M. Baycheva, P. Hadjiiski, D. Konfinova, C. Zhelev (Sofia, BG)

170. Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn’s disease: Systematic review and meta-analysis
D.E. Yung, Y.S. Tham, S. Fay, T. Yamamoto, S. Ben-Horin, R. Eliakim, A. Koulaouzidis, U. Kopylov (Edinburgh, GB; Tel-Aviv, IL; Mie, JP)

171. Entero-MRI in Crohn’s disease: Predictive value of the inflammatory angiogenesis
H. Zaghouani, S. Majdoub, N. Mallat, F. Bouzaiene, E. Ben Jazia, D. Bakir (Sousse, TN)

172. Role of DWI and ADC maps in Crohn’s disease
H. Zaghouani, S. Majdoub, N. Mallat, F. Bouzaiene, E. Ben Jazia, D. Bakir (Sousse, TN)

173. The evaluation of CD40 and CD80 receptors in the colonic mucosal membrane of children with ulcerative colitis
M. Zakrzewski, M. Maciorkowska, W. Ustymowicz, I. Roszko-Kirpsza, B. Kaminska, A. Szlagatys-Sidorkiewicz, E. Maciorkowska, K. Guzinska-Ustymowicz (Bialystok, Gdansk, PL)

174. Spleen abscess: Rare complication of Crohn’s disease
P. Zalizko, V. Mokricka, M. Pavars, J. Pokrotnieks, A. Pukitis (Riga, LV)
175. Toxic myocarditis as a consequence of change in mesalamine therapy
S. Zgradic, D. Popovic, S. Djuranovic, S. Lukic, I. Jovicic, M. Spuran,
S. Dragasevic, L. Toncev, A. Sokic-Mllutinovic (Belgrade, RS)

176. Extraintestinal manifestations of pediatric inflammatory bowel disease
– Experience from a tertiary center
C. Zhelev, P. Yaneva, R. Shentova, M. Baycheva, P. Hadjiiski, D. Kofinova
(Sofia, BG)
List of Speakers, Moderators and Scientific Organizers

Prof. Dr. Matthieu Allez
Service de Gastroentérologie
Hôpital Saint-Louis
1 Ave. C. Vellefaux
75010 Paris
France
matthieu.allez@aphp.fr

Dr. Manuel Barreiro de Acosta
Gastroenterology/
Inflammatory Bowel Disease Unit
University Hospital of Santiago
Choupana S/N
15706 Santiago de Compostela
Spain
manubarreiro@hotmail.com

Prof. Dr. Laurent Beaugerie
Service d’Hépatogastroentérologie
Hôpital Saint-Antoine
184, Rue du Faubourg St.-Antoine
75571 Paris
France
laurent.beaugerie@sat.aphp.fr

Dr. Paula Borralho
Instituto de Anatomia Patológica da
Faculdade de Medicina de Lisboa &
Serviço de Anatomia Patológica
Hospital Cuf Descobertas
Rua Mário Botas
1998-018 Lisboa
Portugal
paula.b.nunes@jmellosaude.pt

Prof. Dr. Yoram Bouhnik
Department of Gastroenterology
Hôpital Beaujon
100, Bd. Général Leclerc
92118 Clichy
France
yoram.bouhnik@gmail.com

Prof. Dr. Franck Carbonnel
Service d’Hépatogastroentérologie
CHU de Bicêtre
Université Paris Sud
78 rue du Général Leclerc
94275 Le Kremlin Bicêtre
France
franck.carbonnel@bct.aphp.fr

Dr. Fátima Carneiro
Department of Pathology
Faculty of Medicine
University of Porto (IPATIMUP)
Rua Dr. Roberto Frias S/N
4200-465 Porto
Portugal
fcarneiro@ipatimup.pt

Dr. Luis A. Correia
Servicio de Medicina II
Faculdade Medicina Lisboa
Hospital Santa Maria
Av. Prof. Egas Moniz
1649-001 Lisbon
Portugal
laraujocorreia@gmail.com

Prof. Dr. André D’Hoore
Department of Abdominal Surgery
University Hospital Leuven
Herestraat 49
3000 Leuven
Belgium
andre.dhoore@uz.kuleuven.ac.be

Prof. Dr. Axel Dignass
Medizinische Klinik I
AGAPLESION
Markus Krankenhaus
Wilhelm-Epstein-Str. 4
60431 Frankfurt
Germany
axel.dignass@fdk.info
Dr. Abraham R. Eliakim  
Department of Gastroenterology  
Chaim Sheba Medical Center  
2 Sheba Road  
52 621 Tel Hashomer  
Israel  
abraham.eliakim@sheba.health.gov.il

Prof. Dr. Arzu Ensari  
Department of Pathology  
Ankara University Medical School  
Sihhiye Ankara 06100  
Turkey  
ensariarzu@gmail.com

Dr. Brian G. Feagan  
c/o Robarts Clinical Trials Inc  
100 Dundas Street, Suite 200  
London, ON N6A 5B6  
Canada  
brian.feagan@robartsinc.com

Claudio Fiocchi, M.D.  
Professor of Medicine  
Pathobiology / NC 20  
The Cleveland Clinic Foundation  
9500 Euclid Avenue  
Cleveland, OH 44195  
USA  
fiocchc@ccf.org

Dr. Gionata Fiorino  
Humanitas Research Hospital  
Via Manzoni 56  
20089 Rozzano  
Italy  
gionataf@gmail.com

Prof. Dr. Karel Geboes  
Department of Pathology  
University Hospital K.U.L. Gasthuisberg  
Herestraat 49  
3000 Leuven  
Belgium  
karel.geboes@skynet.be

Prof. Dr. Subrata Ghosh  
Institute of Translational Medicine  
University of Birmingham  
Birmingham B15 2TT  
Great Britain  
s.ghosh@bham.ac.uk

Prof. Dr. Paolo Gionchetti  
Istituto di Clinica e Gastroenterologia  
Policlinico S. Orsola  
Università di Bologna  
Via Massarenti 9  
40138 Bologna  
Italy  
paolo.gionchetti@unibo.it

Prof. Dr. Javier P. Gisbert  
Hospital de la Princesa  
Diego de Leon 62  
28006 Madrid  
Spain  
javier.gisbert@gmail.com

Dr. Fernando Gomollón  
Hospital Clinico Universitario  
Losano Blesa  
Avenida San Juan Bosco 15  
50009 Zaragoza  
Spain  
fgomollon@gmail.com

Dr. Jonas Halfvarson  
Department of Internal Medicine  
Örebro University Hospital  
70185 Orebro  
Sweden  
jonas.halfvarsson@regionorebrolan.se

Prof. Dr. Peter Kienle  
Chirurgie  
Universitätsklinikum Mannheim  
Theodor-Kutzer-Ufer 1-3  
68167 Mannheim  
Germany  
peter.kienle@umm.de
Dr. Andreas Münch
Division of Gastroenterology
Department of Medicine
School of Medicine
Linköping University Hospital
581 85 Linköping
Sweden
andreas.munch@regionostergotland.se

Prof. Dr. Markus F. Neurath
Medizinische Klinik I
Universitätsklinikum Erlangen
Ulmweg 18
91054 Erlangen
Germany
markus.neurath@uk-erlangen.de

Darrell S. Pardi, M.D.
Gastroenterology & Hepatology
Mayo Clinic
200, First Street SW
Rochester, MN 55905
USA
pardi.darrell@mayo.edu

Dr. Francisco Portela
Servico de Gastroenterologia
Centro Hospitalar e
Universitario de Coimbra HUC
Av. Bissaya Barreto s/n
3000-075 Coimbra
Portugal
fasportela@gmail.com

Florian Rieder, M.D.
Department of Pathobiology
Lerner Research Institute
The Cleveland Clinic Foundation
9500, Euclid Avenue
Cleveland, OH 44195
USA
riederf@ccf.org

Prof. Dr. Dr. Gerhard Rogler
Klinik für Gastroenterologie
& Hepatologie
Universitätsspital Zürich
Rämistr. 100
8091 Zürich
Switzerland
gerhard.rogler@usz.ch

William J. Sandborn, M.D.
Professor of Medicine
Division of Gastroenterology
University of California San Diego
9500 Gilman Drive, MC 0956
La Jolla, CA 92093
USA
wsandborn@ucsd.edu

Bruce E. Sands, M.D.
Professor of Medicine
Department of Gastroenterology
Mount Sinai School of Medicine
One Gustave L. Levy Place
New York, NY 10029
USA
bruce.sands@mssm.edu

Prof. Dr. Stefan Schreiber
Klinik für Innere Medizin I
Universitätsklinikum
Schleswig-Holstein, Campus Kiel
Arnold-Heller-Str. 3 (Haus 6)
24105 Kiel
Germany
s.schreiber@mucosa.de

Prof. Dr. Britta Siegmund
Medizinische Klinik für Gastroenterologie,
Infektiologie und Rheumatologie
Charité Universitätsmedizin
Campus Benjamin Franklin
Hindenburgdamm 30
12203 Berlin
Germany
britta.siegmund@charite.de

Prof. Dr. Harry Sokol
Service d’Hepato-
Gastroentérologie
Hôpital Saint-Antoine
184, rue du Faubourg St. Antoine
75571 Paris
France
harry.sokol@sat.aphp.fr
Prof. Dr. Antonino Spinelli  
Unità Operativa di Chirurgia del Colon e del Retto  
Istituto Clinico Humanitas IRCCS  
Via Manzoni, 56  
20089 Rozzano  
Italy  
antonino.spinelli@humanitas.it

Prof. Dr. Andreas Sturm  
Innere Medizin/Gastroenterologie  
DRK-Kliniken Westend  
Spandauer Damm 130  
14050 Berlin  
Germany  
a.sturm@drk-kliniken-berlin.de

Prof. Dr. Gert van Assche  
Department of Gastroenterology  
University Hospital Leuven  
Herestraat 49  
3000 Leuven  
Belgium  
gert.vanassche@uz.kuleuven.ac.be

Prof. Dr. Stephan Vavricka  
Zentrum für Gastroenterologie und Hepatologie  
Vulkanplatz 8  
8048 Zürich  
Switzerland  
stephan.vavricka@hin.ch

Prof. Dr. Severine Vermeire  
Department of Gastroenterology  
University Hospital Leuven  
Herestraat 49  
3000 Leuven  
Belgium  
severine.vermeire@uzleuven.be
Congress Office

During Symposium 210

Estoril Centro de Congressos
Avenida Amaral
2765-192 Estoril
Portugal

Telephone: +49 (0) 175 / 77 95 327

Opening Hours:
Thursday, April 19, 2018 16.00 – 21.00 h
Friday, April 20, 2018 8.00 – 18.00 h
Saturday, April 21, 2018 8.30 – 16.00 h

Admission to Scientific Program

For admission to scientific program your name badge should be clearly visible.

Airport

Lisbon International Airport 30 km from congress venue
http://www.lisbon-airport.com/

Conflicts of Interest

HALF A CENTURY OF PROMOTING MEDICAL EXCHANGE

Conferences that advance medicine and research: 50 years ago, Herbert Falk, MD, PhD, organized a week-long event in Freiburg devoted to the liver – it was his first symposium and the start of an extraordinary success story.

Since then, 207 additional events have been held worldwide, featuring speakers who are pioneers in their fields. To date, more than 130,000 physicians and researchers from around the world have participated in our symposia, and the strong interest in our upcoming events shows that this concept remains appealing. We take great pride in this!

Since the very beginning, all of our events – whether large or small – have been based on the principle of providing neutral continuing medical education that benefits research, treatment, and ultimately the patient.

We would like to offer our deepest thanks to everyone who has participated, and we look forward to further advancing scientific dialogue as we continue to advocate for more knowledge sharing and therapeutic progress!

Allow us to welcome you to the Falk Foundation symposia – now and for many years to come!
HALF A CENTURY OF PROMOTING
MEDICAL EXCHANGE

Conferences that advance medicine and research: 50 years ago, Herbert Falk, MD, PhD, organized a week-long event in Freiburg devoted to the liver – it was his first symposium and the start of an extraordinary success story. Since then, 207 additional events have been held worldwide, featuring speakers who are pioneers in their fields. To date, more than 130,000 physicians and researchers from around the world have participated in our symposia, and the strong interest in our upcoming events shows that this concept remains appealing. We take great pride in this! Since the very beginning, all of our events – whether large or small – have been based on the principle of providing neutral continuing medical education that benefits research, treatment, and ultimately the patient.

We would like to offer our deepest thanks to everyone who has participated, and we look forward to further advancing scientific dialogue as we continue to advocate for more knowledge sharing and therapeutic progress!

Allow us to welcome you to the Falk Foundation symposia – now and for many years to come!

FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany

www.falk-foundation-symposia.org
Crossing New Borders in IBD: Thoughts and Demands – From Mechanisms to Treatment

April 20–21, 2018
Estoril Centro de Congressos
Lisbon, Portugal

Program

Organized by:
FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany
Congress Department
Telephone: +49 (0) 761/15 14-0
Telefax: +49 (0) 761/15 14-359
E-Mail: symposia@falk-foundation-symposia.org
www.falk-foundation-symposia.org

Symposium 210

Awarded with 11 CME credits